WEKO3
アイテム
Efficacy and safety of carbon-ion radiotherapy for lacrimal gland carcinomas with extraorbital extension: a retrospective cohort study
https://repo.qst.go.jp/records/48793
https://repo.qst.go.jp/records/487931c835fc8-d08c-4cdb-b5c1-e695cb8f502e
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2018-04-23 | |||||
| タイトル | ||||||
| タイトル | Efficacy and safety of carbon-ion radiotherapy for lacrimal gland carcinomas with extraorbital extension: a retrospective cohort study | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Hayashi, Kazuhiko
× Hayashi, Kazuhiko× Koto, Masashi× Ikawa, Hiroaki× Ogawa, Kazuhiko× Kamada, Tadashi× 林 和彦× 小藤 昌志× 伊川 裕明× 小川 和彦× 鎌田 正 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Purpose: To evaluate the efficacy and safety of carbon-ion radiotherapy (CIRT) for patients with lacrimal gland carcionmas (LGCs) with extraorbital extension Results: The median follow-up period was 53.7 months. The 5-year local control and overall survival rates were 62% and 65%, respectively. Regarding late toxicities, 12 patients (36.4%) developed Grade 4 optic nerve disorders, including visual losses of the disweased side (N = 8;66.7%), and 1 patient (3.0%) developed a Grade 3 optic nerve disorder. Three patients (9.0%) developed Grade 3 cataracts, 3 (9.0%) developed glaucoma, and 1 (3.0%) developed retinopathy. Two patients (6.1%) had Grade 4 central nervous system necrosis. No Grade 5 late toxicities were observed. The 5-year preservation rate of the ipsilateral eyeball was 86%. Conclusion: Definitive CIRT is effective for LGCs with extraorbital extension with acceptable toxicity. Methods: Thirty-three patients treated with CIRT at our institution were analyzed. Sixteen patients (48.5%) had adenoid cystic carcinoma, 8 (24.2%) had adnocarcinoma not otherwise specified, and 9 (27.3%) had other types of the disease. Thirty patients (90.9%) had T4c tumors. the prescribed doses were 57.6 Gy (relative biological effectiveness [RBE]) (N = 18; 54.5%) and 64.0 gy(RBE) (N = 15;45.5%) in 16 fractions. |
|||||
| 書誌情報 |
Oncotarget 巻 9, 号 16, p. 12932-12940, 発行日 2018-02 |
|||||
| 出版者 | ||||||
| 出版者 | Inpact Journals | |||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 1949-2553 | |||||
| DOI | ||||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | 10.18632/oncotarget.24390 | |||||
